研究目的
The aim of this study was the development of highly selective and specific PSMA probes with enhanced imaging properties, in comparison with 18F-DCFPyL, 18F-PSMA-1007 and 68Ga-PSMA-11.
研究成果
18F-JK-PSMA-7 is a promising candidate for high quality visualization of small PSMA-positive lesions. Excellent preclinical imaging properties justify further preclinical and clinical studies of this tracer.
研究不足
The study acknowledges limitations with respect to pharmacokinetics and detection rates in patients with very low PSA-values (<1 ng/mL) for existing PSMA specific probes, indicating room for the development of more sensitive PSMA specific probes.
1：Experimental Design and Method Selection:
Eight novel 18F-labeled PSMA ligands were prepared and their cellular uptake in PSMA+ LNCaP C4-2 and PSMA– PC-3 cells was compared to that of 18F-DCFPyL. The most promising candidates were evaluated by μPET in healthy rats using PSMA+ peripheral ganglia as a model for small PCa lesions.
2：Sample Selection and Data Sources:
PSMA+ LNCaP C4-2 and PSMA– PC-3 prostate tumor cells were used for in vitro studies. Healthy Long Evans rats were used for in vivo studies.
3：List of Experimental Equipment and Materials:
Focus 220 micro PET scanner (CTI-Siemens, Germany), gamma counter (Wizard 1470, PerkinElmer, Massachusetts, USA), FXNPro module (GE) for automated production of 18F-JK-PSMA-
4：Experimental Procedures and Operational Workflow:
Cellular uptake studies were performed by incubating cells with the PET tracer at 37 °C for 2 and 4 h. For PET evaluation, dynamic PET scans in list mode were performed using a Focus 220 micro PET scanner.
5：Data Analysis Methods:
Data were analyzed using VINCI 4.72 software. Tracer tissue accumulation was measured for the 60–120 min frame and compared between tracers using one-way ANOVA followed by Dunnett's multiple comparisons test.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
